Antimicrobial resistance in Acinetobacter baumannii: From bench to bedside

Table 2 Antimicrobial treatment for MDRAB infections

Regimen	Pathogen	Diseases	Outcome1	Comparator	Ref.
CST + RIF	XDRAB	HAP VAP BSI cIAI	The same in CR (mortality) Better in MR	CST	[367]
CST + RIF	CRAB	VAP	The same in CR + MR	CST	[366]
CST + IPM	XDRAB	BSI	Better in CR (mortality) + MR	CST	[369]
CST + SAM
CST + others
CST + SUL	MDRAB	VAP	The same in CR + MR	CST	[341]
TGC based	MDRAB	Pneumonia	Higher mortality	CST based	[349]
TGC based	MDRAB	HAIs	The same in mortality2 Better in MR	IPM + SAM	[352]
CT	MDRAB	Infections	The same in mortality	MT	[374]

¹“The same” means no significant difference between comparator groups, and “Better” means a significant difference exists between comparator groups;

²Has a statistically significant favorable outcome. MDRAB: Multidrug-resistant A. baumannii; CST: Colistin; IPM: Imipenem; RIF: Rifampicin; SUL: Sulbactam; SAM: Ampicillin/sulbactam; TGC: Tigecycline; HAP: Hospital-associated pneumonia; VAP: Ventilator-associated pneumonia; BSI: Blood stream infection; cIAI: Complicated intra-abdominal infection; HAIs: Healthcare-associated infections; CR: Clinical response; MR: Microbiological response; CT: Combination therapy; MT: Monotherapy.